title: [Extended voriconazole theraphy and long term survival of a patient with invasive central aspergillosis causing stroke].
abstract: Central nervous system (CNS) aspergillosis with stroke has a high mortality and poor prognosis generally. We report a 78-years-old woman with diabetes mellitus, who developed invasive paranasal sinus aspergillosis with the orbital apex syndrome on the right side and cerebral infarction caused by intracranial occlusion of the right internal carotid artery. Based on the presence of a mass lesion in the ethmoid sinus extending to the orbital apex on the right side with cranial CT, the mass lesion was surgically removed and the pathological examination of the surgical specimen revealed aspergillus mold. Immediately after surgery, we initiated treatment with voriconazole 200 mg × 2/day intravenously for 38 days, and then via feeding tube for 86 days until the galactomannan-aspergillus antigen level in the cerebrospinal fluid became negative at 132 days. She is alive now for almost two years without relapse of aspergillosis. There is no definitive guideline for management of patients with CNS aspergillosis concerning the length of drug treatment and the method for monitoring the response for treatment. We believe that measurement of the galactomannan-aspergillus antigen level in the cerebrospinal fluid might be a useful way of monitoring the efficacy of treatment for CNS aspergillosis.
authors.affiliation: Department of Neurology, Osaka Police Hospital.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Okazaki
authors.forename: Shoichi
authors.initials: S
authors.lastname: Shiraishi
authors.forename: Naoki
authors.initials: N
authors.lastname: Iwasa
authors.forename: Emi
authors.initials: E
authors.lastname: Kitamura
authors.forename: Tetsu
authors.initials: T
authors.lastname: Mizutani
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Hanada
authors.forename: Takehiko
authors.initials: T
authors.lastname: Yanagihara
mesh_terms: D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage*; D000946:Antigens, Fungal / Q000134:cerebrospinal fluid; D001157:Arterial Occlusive Diseases / Q000209:etiology; D001228:Aspergillosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002343:Carotid Artery, Internal; D002493:Central Nervous System Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D048909:Diabetes Complications; D003952:Diagnostic Imaging; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D007262:Infusions, Intravenous; D008351:Mannans / Q000134:cerebrospinal fluid; D010254:Paranasal Sinus Diseases / Q000150:complications; D020521:Stroke / Q000209:etiology* / Q000401:mortality; D013534:Survival; D013997:Time Factors; D065819:Voriconazole / Q000008:administration & dosage*
chemical_list: D000935:Antifungal Agents; D000946:Antigens, Fungal; D015415:Biomarkers; D008351:Mannans; C012990:galactomannan; D065819:Voriconazole; D005690:Galactose